U.S. Markets closed

Ono Pharmaceutical Co., Ltd. (4528.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
2,485.00+59.00 (+2.43%)
As of 10:19AM JST. Market open.

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Osaka 541-8564
81 6 6263 5670

IndustryDrug Manufacturers—General
Full Time Employees3,607

Key Executives

NameTitlePayExercisedYear Born
Mr. Gyo SagaraCEO, Pres & Representative DirectorN/AN/AN/A
Mr. Shozo MatsuokaCorp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QAN/AN/AN/A
Yukio TaniCorp. Exec. Officer & Head of Corp. CommunicationsN/AN/AN/A
Mr. Hiroshi IchikawaCorp. Sr. Exec. Officer and Exec. Director of Sales & MarketingN/AN/AN/A
Mr. Isao OnoExec. Officer, Director of Corp. Research & DirectorN/AN/AN/A
Mr. Toichi TakinoSr. Exec. Officer, Exec. Director of Discovery & Research and DirectorN/AN/AN/A
Mr. Toshihiro TsujinakaSr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and DirectorN/AN/AN/A
Kiyoaki IdemitsuCorp. Exec. Officer, Exec. Director of Clinical Devel. & DirectorN/AN/AN/A
Shinji Takai M.D.Corp. Officer, Head of Medical Affairs & Head of Data StrategyN/AN/AN/A
Satoshi TakahagiBus. Unit Director for Oncology Bus. Unit, Sales & MarketingN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.


Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Corporate Governance

Ono Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.